Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 15, 2019 - Issue 1
Submit an article Journal homepage
423
Views
16
CrossRef citations to date
0
Altmetric
Drug Profile

Tildrakizumab for the treatment of psoriasis

Rodney SinclairDepartment of Medicine, University of Melbourne, Melbourne, AustraliaCorrespondence[email protected]
View further author information
&
Vetrichevvel Thirthar PalaniveluCurtin Medical School, Curtin University, Perth, AustraliaView further author information
Pages 5-12 | Received 17 Jul 2018, Accepted 01 Nov 2018, Published online: 14 Nov 2018

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, Luigi Fornaro, Luca Potestio, Angelo Ruggiero & Matteo Megna. (2023) Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data. Clinical, Cosmetic and Investigational Dermatology 16, pages 2525-2536.
Read now
Angelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo & Matteo Megna. (2023) Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Clinical, Cosmetic and Investigational Dermatology 16, pages 529-536.
Read now
Angelo Ruggiero, Vincenzo Picone, Fabrizio Martora, Gabriella Fabbrocini & Matteo Megna. (2022) Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clinical, Cosmetic and Investigational Dermatology 15, pages 1649-1658.
Read now

Articles from other publishers (13)

Lisza Niarisessa, Anisa Nova Puspitaningrum, Arief Rahman Afief, Dyah Aryani Perwitasari, Wirawan Adikusuma, Rocky Cheung, Abdi Wira Septama & Lalu Muhammad Irham. (2023) Identification of Biological Risk Genes and Candidate Drugs for Psoriasis Vulgaris by Utilizing the Genomic Information. Borneo Journal of Pharmacy 6:2, pages 110-119.
Crossref
Henry Lee, Timothy L. Cowan, Benjamin S. Daniel & Dédée F. Murrell. (2023) A review of JAK and IL ‐23 inhibitors to treat vitiligo . Australasian Journal of Dermatology 64:2, pages 204-212.
Crossref
Sonali Batta, Ramlah Khan, Marcus Zaayman, Allison Limmer, Dario Kivelevitch & Alan Menter. (2023) IL-17 and -23 Inhibitors for the Treatment of Psoriasis. EMJ Allergy & Immunology.
Crossref
Federico Bardazzi, Filippo Viviani, Bianca Maria Piraccini, Claudia Lasagni, Laura Bigi, Marco Manfredini, Linda Pongetti, Vito Di Lernia, Monica Corazza & Francesca Pepe. (2023) Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy). Journal of Cutaneous Medicine and Surgery 27:2, pages 126-132.
Crossref
Angelo Ruggiero, Luca Potestio, Sara Cacciapuoti, Lucia Gallo, Teresa Battista, Elisa Camela, Gabriella Fabbrocini & Matteo Megna. (2022) Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study. Dermatologic Therapy 35:12.
Crossref
Gangadhar Hari, Anoop Kishore & Sreedhara Ranganath Pai Karkala. (2022) Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?. European Journal of Pharmacology 929, pages 175147.
Crossref
Wei-Yu Chen, Shao-Chuan Chen, Shou-Yi Hsu, Yu-An Lin, Chun-Ming Shih, Chun-Yao Huang, Kuo-Hsien Wang & Ai-Wei Lee. (2022) Annoying Psoriasis and Atopic Dermatitis: A Narrative Review. International Journal of Molecular Sciences 23:9, pages 4898.
Crossref
Adela Markota Čagalj, Branka Marinović & Zrinka Bukvić Mokos. (2022) New and Emerging Targeted Therapies for Hidradenitis Suppurativa. International Journal of Molecular Sciences 23:7, pages 3753.
Crossref
Julie Hong, Edward Hadeler, Megan Mosca, Mimi Chung, Samuel Yeroushalmi, Marwa Hakimi, Wilson Liao & Tina Bhutani. (2021) Biologics update: IL‐23 inhibitors. Dermatological Reviews 2:5, pages 276-281.
Crossref
Ashod Kherlopian & Gayle Fischer. (2021) Disease remission of refractory vulvovaginal and gingival lichen planus with tildrakizumab. Australasian Journal of Dermatology 62:2, pages 246-247.
Crossref
Edward Hadeler, Megan Mosca, Julie Hong, Nicholas Brownstone, Tina Bhutani & Wilson Liao. (2021) Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors. Current Dermatology Reports 10:1, pages 6-15.
Crossref
Doreen M. Floss, Jens M. Moll & Jürgen Scheller. (2020) IL-12 and IL-23—Close Relatives with Structural Homologies but Distinct Immunological Functions. Cells 9:10, pages 2184.
Crossref
Lazaros I. Sakkas, Efterpi Zafiriou & Dimitrios P. Bogdanos. (2019) Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis. Frontiers in Pharmacology 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.